Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 Recruiting Phase 3 Trials for Irinotecan (DB00762)

IndicationStatusPhase
DBCOND0113388 (Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8)Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT05677490mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric AdenocarcinomaTreatment